SCHEMBL9924064

SCHEMBL9924064

CCOC(=O)N[C@H]1CC[C@H](N/C(=N\C(=O)c2ccc(F)c(F)c2)NCc2ccc(Cl)cc2F)CC1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.40
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTR7 P34969 1/20 0.38
CXCR3 P49682 2/20 0.36
MCHR1 Q99705 4/20 0.36
P2RX7 Q99572 5/20 0.36
CYP2C9 P11712 1/20 0.35
MAPK14 Q16539 1/20 0.35
HTT P42858 1/20 0.34
F2 P00734 1/20 0.34
DDR1 Q08345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923858 0.92 ALDH1A1 (0.41) CHRM1LMNASMN1; SMN2MCHR1P2RX7
SCHEMBL9924065 0.90 P2RX7 (0.42) P2RX7
SCHEMBL9924274 0.89 CHRM1 (0.41) CHRM1ROCK2ROCK1MCHR1CYP2C9
SCHEMBL9924273 0.89 CHRM1 (0.41) CHRM1LMNASMN1; SMN2MCHR1CYP2C9
SCHEMBL9924270 0.89 HPGD (0.40) CHRM1LMNASMN1; SMN2MCHR1P2RX7
SCHEMBL9924267 0.88 SMN1; SMN2 (0.47) CHRM1ROCK2ROCK1LMNASMN1; SMN2
SCHEMBL9923859 0.88 CHRM1 (0.41) CHRM1ROCK2ROCK1LMNASMN1; SMN2
SCHEMBL9924272 0.87 P2RX7 (0.41) ROCK2ROCK1LMNAHTR7MCHR1
SCHEMBL9923856 0.86 CHRM1 (0.42) CHRM1ROCK2ROCK1LMNASMN1; SMN2
SCHEMBL9924063 0.86 SMN1; SMN2 (0.43) CHRM1LMNASMN1; SMN2MCHR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed